Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
saccharomyces boulardii + superoxide dismutase
- Development stage
- Preclinical
- Lead developer
- Biocodex
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Administration
- Oral
01
Overview
This is a combination dietary supplement containing the probiotic yeast *Saccharomyces boulardii* (a strain of *Saccharomyces cerevisiae*) and the antioxidant enzyme superoxide dismutase (SOD). *S. boulardii* acts as a probiotic, modulating gut microbiota, supporting intestinal barrier function, and exerting anti-inflammatory effects. Superoxide dismutase is an endogenous antioxidant enzyme that catalyzes the conversion of superoxide radicals to hydrogen peroxide and oxygen, thereby reducing oxidative stress. The combination has been studied for its potential benefits in obesity management by decreasing body weight, fat mass, insulin resistance (HOMA-IR), uric acid levels, and systemic inflammation in obese adults. Animal studies also suggest reduced risk of metabolic syndrome associated with obesity when using this combination[1][2][3][5]. The product is typically formulated as a dietary supplement rather than a pharmaceutical drug.
- Other names
- saccharomyces cerevisiae var boulardii + superoxide dismutaseS. boulardii + SOD
Beyond the preview
Go deeper on saccharomyces boulardii + superoxide dismutase.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on saccharomyces boulardii + superoxide dismutase.